Johnson & Johnson JNJ will report its second-quarter 2024 earnings on Jul 17. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $22.38 billion and $2.71 per share, respectively. Earnings estimates for JNJ have declined from $10.64 per share to $10.50 per share for 2024 and from $10.92 per share to $10.86 per share for 2025 over the past 60 days. JNJ Estimate Movement Zacks Investment Research Image Source: Zacks Investment Research Earnings Surprise History The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 4.09%, on average. In the last reported quarter, the company delivered an earnings surprise of 2.65%. Zacks Investment Research Image Source: Zacks Investment Research J&J has an Earnings ESP of -0.74% and a Zacks Rank #3 (Hold). Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Factors Shaping Upcoming Results Sales in J&J’s Innovative Medicines segment (previously the Pharmaceutical segment) are expected to have been driven by higher sales of key products such as Darzalex, Stelara, Tremfya and Erleada due to strong market growth and share gains. The Zacks Consensus Estimate for Stelara sales is pegged at $2.85 billion, while our model projects sales of $2.76 billion. For Darzalex, the consensus mark is pegged at $2.89 billion, while our model estimates sales of $2.97 billion. The Zacks Consensus Estimate for Tremfya is $870 million, while our model estimate is $838.9 million. The consensus estimate for Erleada sales is $691.6 million, while our model projects sales to be $682.5 million. Other products like Invega Sustenna and Uptravi are likely to show growth. The rapid adoption of new drugs like Carvykti, Tecvayli, Talvey and Spravato are likely to have contributed to top-line growth. However, lower sales of its key medicine, Imbruvica and COVID-19 vaccine are likely to have hurt the top line in the second quarter. Rising competitive pressure in the United States from novel oral agents is also likely to have hurt sales of Imbruvica. The Zacks Consensus Estimate for Imbruvica is $732.7 million, while our model indicates sales to be $744.2 million. Generic/biosimilar competition for drugs like Zytiga and Remicade is likely to have hurt the top line. Overall, Innovative Medicine sales growth is expected to be slightly stronger in the first half of the year compared to the second half due to the potential entry of Stelara biosimilars in Europe in mid-2024. The Zacks Consensus Estimate for J&J’s Innovative Medicine unit is $14.17 billion, while our estimate is $14.0 billion. In the first quarter, MedTech segment sales were hurt by fewer selling days, disproportionately impacting orthopedics. This negative impact was not there in the second quarter and sales are likely to have improved sequentially. Continued recovery in worldwide procedure volumes and uptake from recently launched products are expected to have driven sales in the second quarter. However, the impact of volume-based procurement (VBP) issues in China in some categories might have hurt sales to some extent. The Zacks Consensus Estimate for J&J’s MedTech segment is $8.33 billion, while our model estimate is $8.21 billion. Nonetheless, a single quarter’s results are not so important for long-term investors. Let us delve deeper to understand whether to buy, sell or hold J&J’s stock. Price Performance & Valuation Year to date, J&J’s stock has declined 4.4% against an increase of 24.2% for the industry. The stock has also underperformed the sector as well as the S&P 500. JNJ Stock Underperforms Industry, Sector & S&P 500 Zacks Investment Research Image Source: Zacks Investment Research From a valuation standpoint, J&J appears attractive relative to the industry and is trading below its mean. Going by the price/earnings ratio, the company shares currently trade at 14.02 forward earnings, lower than 20.72 for the industry and the stock’s mean of 16.07. The stock is also trading near its 52-week low. JNJ Stock Valuation Zacks Investment Research Image Source: Zacks Investment Research J&J’s biggest strength is its diversified business model. With last year’s complete separation of the Consumer Health segment into a newly listed company called Kenvue KVUE, J&J has now become a two-sector company focused on the Pharmaceutical and MedTech fields. J&J’s Innovative Medicine (previously Pharmaceuticals) and MedTech segments have shown a growth trend and the same is likely to continue in the years ahead. J&J is making rapid progress with its pipeline and line extensions. The company has sufficient funds to pursue bolt-on acquisitions and deals to boost its portfolio. The company is also returning value to shareholders through share buybacks and dividend payments. It has hiked its dividends for 62 consecutive years. Its current dividend yield of around 3.4% is attractive. However, the company is likely to continue to incur billions of dollars for legal expenses in future quarters due to its pending talc-based lawsuits. The lawsuits allege that its talc products contain asbestos, which caused many women to develop ovarian cancer. Conclusion No matter how the second-quarter results play out, we suggest a new investor should avoid buying J&J stock right now due to the uncertainty surrounding its legal battles. An investor interested in buying a large drugmaker may consider investing in Vertex Pharmaceuticals VRTX instead, which has a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here. However, those who already own J&J stock may stay invested as the company is generating decent sales and profit growth, a trend likely to have continued in the second quarter. If J&J can manage to completely resolve its talc lawsuits, it will remove a significant overhang on the stock and make it an attractive investment. Long-term investors may consider buying J&J’s stock at the present cheap valuation. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ):Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX):Free Stock Analysis Report Kenvue Inc. (KVUE):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...